Study of ORL-1G (D-galactose) in Patients With Glycogen Storage Disease Type 14
NCT ID: NCT03404856
Last Updated: 2019-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
5 participants
INTERVENTIONAL
2017-10-31
2019-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Prebiotics on GLP-1 in Type 2 Diabetes
NCT02569684
Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy
NCT04159415
A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes
NCT01771250
A Study of Intracellular Signaling in Muscle and Fat Cells During Ketosis
NCT02157155
GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis
NCT01451905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment with ORL-1G - D-galactose
ORL-1G - D-galactose
Oral ORL-1G - D-galactose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ORL-1G - D-galactose
Oral ORL-1G - D-galactose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Less than 18 years old.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Orpha Labs
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Orpha Labs
Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GALA-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.